Trends in net survival from skin malignant melanoma in six European Latin countries: Results from the SUDCAN population-based study

J. Galceran, Z. Uhry, R. Marcos-Gragera, J. Borràs, Diego Serraino, Antonella Zucchetto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90% (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9% in Italy and Spain vs. +2% in Switzerland or +4% in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)S77-S84
Number of pages8
JournalEuropean Journal of Cancer Prevention
Volume26
Issue numbersupp 1
DOIs
Publication statusPublished - 2017

Fingerprint

Melanoma
Skin
Survival
Population
Switzerland
Portugal
Spain
Italy
France
Belgium
Mortality
Health Policy
Immunotherapy
Early Diagnosis
Age Groups
Demography
Databases
Health

Keywords

  • Cancer registries
  • Europe
  • Excess mortality rate
  • Latin countries
  • Net survival
  • Skin melanoma
  • Trend analysis
  • adult
  • aged
  • Article
  • Belgium
  • cancer mortality
  • cancer survival
  • cutaneous melanoma
  • female
  • follow up
  • France
  • groups by age
  • health care policy
  • human
  • Italy
  • major clinical study
  • male
  • middle aged
  • multicenter study
  • Portugal
  • priority journal
  • Spain
  • Switzerland
  • very elderly

Cite this

Trends in net survival from skin malignant melanoma in six European Latin countries: Results from the SUDCAN population-based study. / Galceran, J.; Uhry, Z.; Marcos-Gragera, R.; Borràs, J.; Serraino, Diego; Zucchetto, Antonella.

In: European Journal of Cancer Prevention, Vol. 26, No. supp 1, 2017, p. S77-S84.

Research output: Contribution to journalArticle

@article{199205e5b02e4e6fb062c30ce435f245,
title = "Trends in net survival from skin malignant melanoma in six European Latin countries: Results from the SUDCAN population-based study",
abstract = "In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90{\%} (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9{\%} in Italy and Spain vs. +2{\%} in Switzerland or +4{\%} in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment. Copyright {\circledC} 2017 Wolters Kluwer Health, Inc. All rights reserved.",
keywords = "Cancer registries, Europe, Excess mortality rate, Latin countries, Net survival, Skin melanoma, Trend analysis, adult, aged, Article, Belgium, cancer mortality, cancer survival, cutaneous melanoma, female, follow up, France, groups by age, health care policy, human, Italy, major clinical study, male, middle aged, multicenter study, Portugal, priority journal, Spain, Switzerland, very elderly",
author = "J. Galceran and Z. Uhry and R. Marcos-Gragera and J. Borr{\`a}s and Diego Serraino and Antonella Zucchetto",
note = "Export Date: 20 February 2018 CODEN: EJUPE Correspondence Address: Galceran, J.; Tarragona Cancer Registry, Foundation Society for Cancer Research and Prevention, IISPV, Rovira i Virgili University, Thematic Network of Cooperative Research in CancerSpain; email: jgalceran@grupsagessa.com",
year = "2017",
doi = "10.1097/CEJ.0000000000000306",
language = "English",
volume = "26",
pages = "S77--S84",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "supp 1",

}

TY - JOUR

T1 - Trends in net survival from skin malignant melanoma in six European Latin countries: Results from the SUDCAN population-based study

AU - Galceran, J.

AU - Uhry, Z.

AU - Marcos-Gragera, R.

AU - Borràs, J.

AU - Serraino, Diego

AU - Zucchetto, Antonella

N1 - Export Date: 20 February 2018 CODEN: EJUPE Correspondence Address: Galceran, J.; Tarragona Cancer Registry, Foundation Society for Cancer Research and Prevention, IISPV, Rovira i Virgili University, Thematic Network of Cooperative Research in CancerSpain; email: jgalceran@grupsagessa.com

PY - 2017

Y1 - 2017

N2 - In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90% (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9% in Italy and Spain vs. +2% in Switzerland or +4% in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

AB - In Europe as a whole, survival from skin malignant melanoma (SMM) has increased constantly since the 1980s. The aim of the SUDCAN collaborative study was to compare the trends in the 5-year net survival from SMM and in related excess mortality rate between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland). The data were extracted from the EUROCARE-5 database (end of follow-up: 01 January 2009). First, the net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. The analyses were carried out using a flexible excess rate modeling. Over the 2000-2004 period, the 5-year net survival from SMM ranged from 79 (Portugal) to 90% (Switzerland). In all countries, net survival was higher in women versus men and in young versus old age groups. From 1992 to 2004, the 5-year net survival increased the most in the countries with the lowest survivals in 1992 (+9% in Italy and Spain vs. +2% in Switzerland or +4% in France). The differences between countries decreased between 1992 and 2004. Although survival increased to a lower or higher extent in all countries during the period studied, significant differences in net survival from SMM persisted among the six countries studied. Health policies should mainly enhance early diagnosis by increasing public awareness and with screening campaigns. Furthermore, new immunotherapies, which will be approved soon hopefully, should also be used to improve the outcomes of SMM treatment. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

KW - Cancer registries

KW - Europe

KW - Excess mortality rate

KW - Latin countries

KW - Net survival

KW - Skin melanoma

KW - Trend analysis

KW - adult

KW - aged

KW - Article

KW - Belgium

KW - cancer mortality

KW - cancer survival

KW - cutaneous melanoma

KW - female

KW - follow up

KW - France

KW - groups by age

KW - health care policy

KW - human

KW - Italy

KW - major clinical study

KW - male

KW - middle aged

KW - multicenter study

KW - Portugal

KW - priority journal

KW - Spain

KW - Switzerland

KW - very elderly

U2 - 10.1097/CEJ.0000000000000306

DO - 10.1097/CEJ.0000000000000306

M3 - Article

VL - 26

SP - S77-S84

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - supp 1

ER -